Abstract：【Objective】 To investigate the efficacy of empagliflozin combined with metformin in the treatment of elderly patients with type 2 diabetes (T2DM) and their effects on levels of blood glucose, interleukin-17A (IL-17A), IL-22, and interferon-γ (IFN-γ). 【Methods】 A total of 108 elderly patients with type 2 diabetes in our hospital from January 2020 to July 2020 were selected and divided into the observation group (n=54) and the control group (n=54) based on a simple random number table method. On the basis of routine intervention, patients in the control group received metformin alone for 3 months' treatment, while patients in the observation group received both metformin and empagliflozin for 3 months. The clinical efficacy, blood glucose indicators [fasting blood glucose (FPG), 2 h postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c)], islet function indicators [fasting insulin (FINS), 2 h postprandial insulin ( PINS), insulin resistance index (HOMA-IR), pancreatic islet β cell function index (HOMA-β)],IL-17A, IL-22, IFN-γ levels, blood lipids [low density lipoprotein cholesterol (LDL-C), High-density lipoprotein cholesterol (HDL-C), triacylglycerol (TG), total cholesterol (TC)], blood pressure [diastolic blood pressure (DBP), systolic blood pressure (SBP)], BMI before and after treatment, and the incidence of adverse reactions were calculated and compared between the two groups. 【Results】 The total effective rate of the observation group (94.44%) was higher than that of the control group (81.48%) (P<0.05). The levels of FPG, 2hPG, HbA1c HOMA-IR, IL-17A, IL-22, IFN-γ, LDL-C, TG, TC, DBP, and SBP in the observation group were lower than those in the control group after 1 month and 3 months of treatment (P<0.05); While after 1 month and 3 months of treatment, the levels of HOMA-β, FINS, HDL-C and PINS in the observation y group were higher than those in the control group, the differences were all statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group (9.26%) and the control group (5.56%) (P>0.05). 【Conclusion】 Metformin combined with empagliflozin in the treatment of elderly type 2 diabetes can effectively reduce blood glucose, improve islet function, regulate blood lipids and blood pressure, reduce BMI, improve therapeutic effects, and down-regulate serum IL-17A, IL-22. It is worthy of clinical application.
[1] 杨哲普,毕会民.恩格列净与DDP4抑制剂治疗2型糖尿病疗效比较的Meta分析[J].医学研究杂志,2017,46(4):116-123.
[2] 黎风,何梅,邵鑫,等.达格列净联合二甲双胍治疗2型糖尿病的药物经济学系统评价[J].中国药房,2018,29(9):1259-1263.
[3] 陈显建,商永光.恩格列净治疗2型糖尿病不良反应的Meta-分析[J].药物评价研究,2019,42(1):164-170.
[4] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.
[5] 陈诚,邓斌.恩格列净联合利格列汀治疗2型糖尿病的临床研究[J].药物评价研究,2020,43(5):880-884.
[6] 干异,杨成会.西格列汀联合二甲双胍对2型糖尿病患者糖、脂代谢及胰岛素抵抗的影响[J].中国煤炭工业医学杂志,2017,20(12):1442-1446.
[7] 许先锋.双胍类药物对老年T2DM患者肠道菌群及糖脂代谢水平的影响[J].医学临床研究,2020,37(7):1048-1050.
[8] 张思敏,韩学尧,纪立农.二甲双胍治疗2型糖尿病的药物基因组学研究进展[J].中国糖尿病杂志,2017,25(8):760-764.
[9] 刘金永,李子玥,王昕雯.恩格列净联合二甲双胍治疗2型糖尿病疗效和安全性的Meta分析[J].实用临床医药杂志,2019,23(16):70-75.
[10] MERKER L,HARING H U,CHRISTIANSEN A V,et al.Empagliflozin as add-on to metformin in people with Type 2 diabetes[J].Diabet Med,2016,32(12):1555-1567.
[11] 庞宁,陈科,彭皓均,等.阿卡波糖联合二甲双胍对2型糖尿病患者相关指标的影响[J].中国药房,2017,28(27):3774-3777.
2021, Vol. 38 
